Braidwell’s Tourmaline Bio TRML Stock Holding History

Braidwell’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-906,820	Closed	-$20.8M	–	84
2024 Q1	$20.8M	Hold	906,820	–	–	0.67%	47
2023 Q4	$23.7M	Buy	+906,820	New	+$18.1M	0.87%	39

Other funds holding TRML

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Braidwell's TRML Position: Q2 2024 in Review

Braidwell sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 906,820 shares — an estimated $20.8M sold.

Braidwell first reported a position in TRML in Q4 2023 and held it in 2 quarters. The position peaked at $23.7M in Q4 2023. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

Braidwell reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
Braidwell sold 906,820 Tourmaline Bio shares in Q2 2024, an estimated $20.8M.
Braidwell first reported a position in Tourmaline Bio in Q4 2023 and held it in 2 quarters.
Braidwell's Tourmaline Bio position peaked at $23.7M in Q4 2023.
84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.